What top creators are saying about Viking Therapeutics, Inc.(VKTX)

The speaker observed that the stock had rallied but stated no recommendation.

The discussion noted shares moving from about $35 toward a bid or deal price near $39 but offered no valuation assessment.

The speaker discussed price movement around $35, $39, and $38 but offered no company-specific investment thesis; these were trading observations, not targets.

The speaker was skeptical about its GLP data, expected further selling, and said he might short more, while noting the chart looked somewhat bullish.

Shkreli questioned the value of Viking's GLP-1 program and raised concerns about limited cash and financing needs. He also mentioned covering a short and possibly going long after a decline, while noting a rebound as potentially positive but remaining uncertain.

A speaker expected further selling, questioning demand for another classic GLP drug, while acknowledging that the chart looked somewhat bullish.

Phase 2 data for VK2735 looks good, but Phase 3 results are long-dated (2027), making it a long-term play.

A bearish sentiment was expressed, with the speaker stating, 'I think Viking is kind of cooked, man,' implying its positive run may be over.

Mentioned as a liked small-cap biotech name that could be an M&A target, potentially leading to sharp stock price increases.

Identified as a key player and a company 'to watch' for investors looking to gain exposure to the GLP-1 theme.

Faces potential headwinds as the speaker believes the weight-loss drug sector is 'over' due to struggles from market leader Novo Nordisk.